Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism”
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index; 16 of the 27 sources its claims cite were checked for support.
Abstract
Hypothyroidism is a frequent disease, and oral levothyroxine is the mainstay of its treatment. However, more than 15% of levothyroxine-treated patients fail to achieve the recommended serum TSH level, and “refractory hypothyroidism” is due to either malabsorption, increased metabolism of thyroxine, or nonadherence to treatment. A levothyroxine absorption test must be used to differentiate true malabsorption from nonadherence or pseudo-malabsorption. We analyzed 166 levothyroxine absorption tests in 143 hypothyroid patients (109 women, mean age 43 ± 1 years) treated with oral levothyroxine. Despite a daily dose of 3.26 ± 0.09 µg/kg/day, mean serum TSH concentration was 25.7 ± 3.7 mU/L. “Refractory hypothyroidism” was in the context of gastritis (24%), Helicobacter pylori infection (18%), drug interference with levothyroxine absorption (15.6%), nonadherence to treatment (10%), celiac disease (2.5%), or bariatric surgery (1.2%). After an overnight fast, patients orally took their daily dose of levothyroxine (220 ± 6 µg), and blood samples were drawn before levothyroxine intake and every 2 hours for 24 hours. After levothyroxine intake, the mean total (basal = 7.64 ± 0.26 µg/dL, peak 9.41 ± 0.28 µg/dL), and free (basal = 12.58 ± 0.42 pg/mL, peak 15.77 ± 0.51 pg/mL) T4 levels increased (P < .001), total and free T4 peaks were observed at 4.2 ± 0.23 and 4.30 ± 9.27 hours, respectively. Levothyroxine absorption tests were well tolerated. In conclusion, in most patients with “refractory hypothyroidism,” this clinical study revealed that the levothyroxine absorption test can be achieved via the absorption of the daily dosage of levothyroxine, and the evaluation of total or free T4 concentrations over 4- or 6-hour follow-up. The test is well tolerated without cardiovascular adverse events.
Overview
CoChat Summary
TL;DR
In 143 patients with “refractory hypothyroidism,” a levothyroxine absorption test using the patient’s daily levothyroxine dose produced measurable total and free T4 increases and was well tolerated. The authors conclude the test can be performed with the daily dose and total or free T4 sampling over 4 to 6 hours.
Key findings
- Across 166 tests in 143 patients (109 women; mean age 43 ± 1 years), mean levothyroxine dose was 220 ± 6 µg/day or 3.26 ± 0.09 µg/kg/day, while mean serum TSH was 25.7 ± 3.7 mU/L in the abstract.
- After daily-dose levothyroxine, total T4 rose from 7.64 ± 0.26 to 9.41 ± 0.28 µg/dL and free T4 from 12.58 ± 0.42 to 15.77 ± 0.51 pg/mL (both P < .001); peaks occurred at 4.2 ± 0.2 and 4.3 ± 0.2 hours, respectively.
- Mean TSH did not change at 24 hours (25.1 ± 3.3 to 25.5 ± 3.4 mU/L, ns). No adverse events were reported during the 24-hour follow-up.
- Percentage absorption was lower in autoimmune/chronic gastritis than in pseudo-malabsorption (60 ± 9% vs 116 ± 19%, P < .01), with lower TT4 and FT4 increases; decreases were also observed with H. pylori infection or proton pump inhibitor treatment.
Methods
- Retrospective analysis of levothyroxine absorption tests performed between January 2006 and December 2023 in patients with TSH above the reference range despite relatively large levothyroxine doses.
- After an overnight fast, patients received their daily levothyroxine dose under supervision; blood was drawn before intake and every 2 hours for 24 hours. Total T4 and free T4 were measured in all samples, and TSH at baseline and in the last sample.
- Percentage levothyroxine absorption was calculated using peak minus baseline TT4, volume of distribution = 0.442 × BMI, and administered dose; <60% indicated malabsorption. Assays were ADVIA Centaur (2006-2014) and Cobas 8000 (2015-2023).
Limitations
- The authors state the study was retrospective and therefore had inherent bias.
- The authors state they did not determine sensitivity and specificity of cutoff total and free T4 values to differentiate malabsorption syndrome from noncompliance.
- The text also notes that using total T4 concentration or percentage absorption may be a limitation because total T4 is influenced by more factors than free T4; assay changes over the study period are evident from the methods and may affect comparability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
9 Valid · 0 Not valid · 3 Not checked · 28 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“So, TSH measurements did not provide additional information in this levothyroxine absorption test [21].”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Discussion
What the sources say
- Supportedcites [21] Santos Monteiro S, Santos TS, Lopes AM, Oliveira JC, Freitas C, Couto Carvalho A. Levothyroxine malabsorption or pseudomalabsorption? A question in the management of refractory hypothyroidism. Endocr Connect. 2022; 11(12): e220355. 36318199 PMC9716372 source
The Discussion explicitly concludes that TSH measurements during the levothyroxine absorption test do not provide relevant information. It explains that TSH did not reliably decline within the six-hour test period, matching the claim about this test. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite a daily levothyroxine dose of more than 1.9 µg/kg/day, between 15% and 20% of levothyroxine-treated patients present hypothyroid symptoms or have TSH levels above the upper limit of the reference range [3, 4].”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Abstract
What the sources say
- Supportedcites [3] Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest. 2017; 40(12): 1289‐ 1301. 28695483 PMC5680379 source
The Background reports that 28% of 2,292 patients receiving thyroid hormone therapy had elevated serum TSH. Its Table 2 lists inadequate-therapy rates of 18%, 27%, 18%, 15%, and 28% across five studies, supporting the claim that more than 15% of levothyroxine-treated patients can miss their TSH target. (LLM, conf=0.90)
- Supportedcites [4] Benvenga S, Papi G, Antonelli A. Refractory hypothyroidism due to improper storage of levothyroxine tablets. Front Endocrinol. 2017; 8: 155. PMC5502408 28740481 source
The Introduction states that approximately 15–20% of patients taking levothyroxine have persistently abnormal serum TSH levels. The Discussion describes approximately 15–20% as having high serum TSH levels, supporting the quoted paraphrase. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In a fasted state, 60% to 80% of the orally administered levothyroxine dose is absorbed”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Abstract
What the sources say
- Supportedcites [1] Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019; 40 (1): 118‐ 136. 30476027 source
In “How oral thyroxine is ingested,” the paper discusses absorption under fasting conditions and states that, on average, 60–80% of ingested T4 is absorbed and rendered bioavailable. This supports the cited claim. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [2] Skelin M, Lucijanic T, Amidzic Klaric D, et al 2017 factors affecting gastrointestinal absorption of levothyroxine: a review. Clin Ther. 2017; 39(2): 378‐ 403. 28153426 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of levothyroxine absorption was negatively correlated with the daily dose of levothyroxine (P < .001).”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Results > Hormonal data
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, only 4 results after the 6-hour levothyroxine absorption test were discordant (2.4%) when hormonal follow-up was prolonged for 24 hours.”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
16 more claims
Create a free account to see all 40 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 11
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Results > Patients
“The causes of hypothyroidism were surgical thyroidectomy for benign (n = 61) or malignant (n = 41) diseases”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Results > Patients
“The mean dose of levothyroxine was 207 ± 7 µg/day and 242 ± 13 µg/day after surgery for benign (n = 104) and malignant (n = 39) diseases, respectively”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“A total of 143 patients underwent levothyroxine absorption testing: they had 1 (n = 125), 2 (n = 11), or more than 3 (n = 4) levothyroxine absorption tests, respectively, and were included in the study.”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Results > Patients
Reported 143 · recomputed 140
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Abstract
“total and free T4 peaks were observed at 4.2 ± 0.23 and 4.30 ± 9.27 hours, respectively.”
§ Levothyroxine Absorption Test With the Daily Levothyroxine Dose in Patients With “Refractory Hypothyroidism” > Results > Hormonal data
“Total and free T4 levels peaked after 4.2 ± 0.2 hours and 4.3 ± 0.2 hours, respectively.”
Citations
Cites
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164 · cited 2×
“Then, levothyroxine absorption takes place primarily in the duodenum and jejunum of the small intestine [1, 2].”
Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review
Skelin, M., Lucijanić, T., Amidžić Klarić, D., Rešić, A., Bakula, M., Liberati-Čizmek, A.-M., Gharib, H., & Rahelić, D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.005 · Cited by 133 · cited 2×
“Then, levothyroxine absorption takes place primarily in the duodenum and jejunum of the small intestine [1, 2].”
Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113 · cited 3×
“In some patients, despite increasing levothyroxine dosage beyond 1.9 µg/kg/day, euthyroid state is not achieved [3, 4].”
InfluentialWalker, J. N., Shillo, P., Ibbotson, V, Vincent, A., Karavitaki, N., Weetman, A. P., Wass, J. A. H., & Allahabadia, A. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-1035 · Cited by 70 · cited 1×
“After high-dose levothyroxine After oral levothyroxine intake, thyroxine levels typically rise in 1 hour and the peak is within the first 3 hours [17].”
Levothyroxine therapy in gastric malabsorptive disorders
Virili, C., Brusca, N., Capriello, S., & Centanni, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.621616 · Cited by 52 · cited 1×
“It is well known that gastric acid pH plays an important role in levothyroxine absorption, and an increased gastric pH decreases the solubility of levothyroxine tablets and can potentially impair absorption of orally administered levothyr-oxine sodium [2, 5, 25, 26].”
The levothyroxine absorption test: a four-year experience (2015-2018) at the Mayo Clinic
Gonzales, K. M., Stan, M. N., Morris, J. C., Bernet, V., & Castro, M. R. (2019) · Thyroid · doi:10.1089/thy.2019.0256 · Cited by 46 · cited 1×
“• Percentage of levothyroxine absorption [11, 19, 20] In which BMI indicates body mass index.”
Bugdaci, M. S., Zuhur, S. S., Sokmen, M., Toksoy, B., Albayrak, B., & Altuntas, Y. (2011) · Helicobacter · doi:10.1111/j.1523-5378.2011.00830.x · Cited by 41 · cited 1×
“It is well known that gastric acid pH plays an important role in levothyroxine absorption, and an increased gastric pH decreases the solubility of levothyroxine tablets and can potentially impair absorption of orally administered levothyr-oxine sodium [2, 5, 25, 26].”
Levothyroxine absorption test to differentiate pseudomalabsorption from true malabsorption
Ghosh, S., Pramanik, S., Biswas, K., Bhattacharjee, K., Sarkar, R., Chowdhury, S., & Mukhopadhyay, P. (2020) · European Thyroid Journal · doi:10.1159/000504218 · Cited by 39
Rapid levothyroxine absorption testing: a case series of nonadherent patients
Balla, M., Jhingan, R. M., & Rubin, D. J. (2015) · International Journal of Endocrinology and Metabolism · doi:10.5812/ijem.31051 · Cited by 30
The clinical utility of free thyroxine in oral levothyroxine absorption testing
Ching Sun, G. E., Pantalone, K. M., Faiman, C., Gupta, M., Olansky, L., & Hatipoglu, B. (2014) · Endocrine Practice · doi:10.4158/ep13487.or · Cited by 27 · cited 1×
“Total and free thyroxine concentrations are correlated highly in patients with severe hypothyroidism [16], as well as in our patients ( P .001), so free thyroxine levels can be used interchangeably with total thyroxine levels in quantitative and qualitative levothyroxine absorption testing [16].”
Pseudomalabsorption of thyroid hormones: case report and review of the literature
Livadariu, E., Valdes‐Socin, H., Burlacu, M. C., Vulpoi, C., Daly, A., & Beckers, A. M. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.09.003 · Cited by 26 · cited 1×
“However, these adverse effects are rarely observed [23] because changes in thyroxine levels are minimal and they remain within the reference range in most patients [24], and T4 is bound by thyroxine-binding globulin and slowly enters the tissues, and also free T4 needs to be converted to T3 first…”
Refractory hypothyroidism due to improper storage of levothyroxine tablets
Benvenga, S., Papi, G., & Antonelli, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00155 · Cited by 22 · cited 2×
“In some patients, despite increasing levothyroxine dosage beyond 1.9 µg/kg/day, euthyroid state is not achieved [3, 4].”
InfluentialThe use of levothyroxine absorption tests in clinical practice
Caron, P., & Declèves, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad132 · Cited by 18 · cited 4×
“…of a high dose (800-2000 µg) of levothyroxine may be associated with side effects such as pal - pitations, angina, or cardiac arrhythmia in a small proportion of patients with lower weight, elderly patients, or those with heart diseases (cardiac arrythmia and coronary artery disease) [20, 22].”
InfluentialSelf-citationRefractory hypothyroidism: unraveling the complexities of diagnosis and management
Quiroz-Aldave, J. E., Concepción-Zavaleta, M. J., Durand-Vásquez, M. D. C., Concepción-Urteaga, L. A., Gamarra-Osorio, E. R., Suárez-Rojas, J., Rafael-Robles, L. D. P., Paz-Ibarra, J., & Román-González, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.003 · Cited by 14
Lewandowski, K. C., Dąbrowska, K., Komorowska-Dudek, I., & Lewiński, A. (2015) · Thyroid Research · doi:10.1186/s13044-015-0028-0 · Cited by 10
Santos Monteiro, S., Santos, T. S., Lopes, A. M., Oliveira, J. C., Freitas, C., & Couto Carvalho, A. (2022) · Endocrine Connections · doi:10.1530/ec-22-0355 · Cited by 9 · cited 1×
“So, TSH measurements did not provide additional information in this levothyroxine absorption test [21].”
Goichot, B., Vinzio, S., Luca, F., Sirlin, X., Sapin, R., & Schlienger, J.-L. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02975.x · Cited by 8 · cited 2×
“…effects are rarely observed [23] because changes in thyroxine levels are minimal and they remain within the reference range in most patients [24], and T4 is bound by thyroxine-binding globulin and slowly enters the tissues, and also free T4 needs to be converted to T3 first to be…”
Alhassan, A. A., Alidrisi, H. A., & Mansour, A. A. (2023) · Cureus · doi:10.7759/cureus.37776 · Cited by 6 · cited 2×
“Levothyroxine absorption test should be simple, safe, and in an outpatient setting, but the levothyroxine absorption testing is not standardized, and variable doses of levothyroxine have been reported in the literature [7-18 , 20].”
Levothyroxine absorption test—results and follow up of patients from a single center
Subramaniam, K., Babu, T., Sreevalsan, K. C., & Mathew, S. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_188_21 · Cited by 4
A Report of the Mayo Clinic Experience on the Levothyroxine Absorption Test
Biondi, B. (2020) · Clinical Thyroidology · doi:10.1089/ct.2020;32.6-8 · Cited by 4 · cited 1×
“In clinical practice, the levothyroxine absorption test is part of the workup of patients with “refractory hypothyroidism” to differentiate true malabsorption from nonadherence or pseudo-malabsorption [3, 6].”
Kiran, Z., Shaikh, K. S., Fatima, N., Tariq, N., & Baloch, A. A. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03760-0 · Cited by 3 · cited 1×
“…of a high dose (800-2000 µg) of levothyroxine may be associated with side effects such as pal - pitations, angina, or cardiac arrhythmia in a small proportion of patients with lower weight, elderly patients, or those with heart diseases (cardiac arrythmia and coronary artery disease) [20, 22].”
Levothyroxine absorption test: a therapeutic strategy for improving medication adherence
Barbar, B., Hossen, S., Quinton, R., James, A., Perros, P., Pearce, S., Napier, C., Gan, E., Mitchell, A., & Mamoojee, Y. H. (2023) · Clinical Endocrinology · doi:10.1111/cen.14902 · Cited by 3
Diagnosis of levothyroxine Pseudo-malabsorption: the results of standardised testing protocol
(2021) · Journal of the College of Physicians and Surgeons Pakistan · doi:10.29271/jcpsp.2021.09.1099 · Cited by 2
Younes, N., Pinto, S., & Valensi, P. E. (2022) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2022.375 · Cited by 2 · cited 2×
“Levothyroxine absorption test should be simple, safe, and in an outpatient setting, but the levothyroxine absorption testing is not standardized, and variable doses of levothyroxine have been reported in the literature [7-18 , 20].”
Research works printed but not linked: 2
- Soares RMV, de Figueiredo RM, Melo Dantas MN, et al Rapid levothyroxine (lt4) absorption test for diagnosis of LT4 pseudomalabsorption: case report and proposal of a cutoff point. J Endocrinol Diabetes Obes. 2016; 4(1): 1083.
- Greenstadt MA, Nicoloff JT, Spencer CA, Kaptein EM. 1981 development of a non-isotopic method for determination of oral T4 absorption. Clin Res. 1981; 29: A83.
Cited by
Beyond the Gut: thyroxine malabsorption, pharmacokinetics, and delivery
Law, L. S., Kuu, N. W. X., Leong, M. H. T., Lo, E. A. G., Yeoh, S. F., & Yang, S. P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag024 · Cited by 2
Refractory Hypothyroidism: Unexpected Outcome During Treatment of Giant Cell Arteritis
Deprince, E., Grunenwald, S., Mouly, C., Benoit, J., & Caron, P. J. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71289
“A levothyroxine absorption test is the “gold standard” for differentiating between impaired gastrointestinal absorption of levothyroxine and poor compliance with treatment or increased clearance of exogenous levothyroxine [4–6].”
Self-citationTroshina, E., Mazurina, N. V., Botasheva, M. H., Platonova, N. M., Pershina-Milyutina, A. P., & Gasymova, I. R. K. (2026) · Problems of Endocrinology · doi:10.14341/probl13665
“Caron P. и соавт. в ретроспективном исследовании оценивали и процент всосавшегося ле-вотироксина с использованием формулы и динамику концентрации общего Т4 и свТ4 [10].”
Refractory hypothyroidism: Diagnostic evaluation and management strategies
Mavromati, M., Jarlborg, P., Demarchi, M. S., & Leboulleux, S. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102489 · Cited by 1
Arzumanyan, K., Bandovkina, A. V., Mazurina, N. V., Botasheva, M. H., & Platonova, N. M. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-1-11
Metadata
- Authors
- Caron, P., Tudor, C., & Grunenwald, S.
- Affiliations
- Hôpital Larrey (FR)
- Corresponding author
- Caron, Philippe
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2025-03-03
- Volume
- 9
- Issue
- 4
- Pages
- bvaf017-bvaf017
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC11879399
- OpenAlex
- W4408146948
- Semantic Scholar
- dd0287eca7535114b613444f6be9f564b3964764
- Cited by
- 8
- References
- 25
- Citations by year
- 2026: 7 · 2025: 1
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Endocrine Society (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- refractory hypothyroidism, thyroxine metabolism, treatment non-adherence, free thyroxine, total thyroxine, serum TSH, gastritis, Helicobacter pylori infection, celiac disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
